microRNAs as markers of survival and chemoresistance in pancreatic ductal adenocarcinoma

References

• Bloomston M, Frankel WL, Petrocca F et al. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA297(17), 1901–1908 (2007).
   PubMed Web of Science ®Google Scholar
• Preis M, Gardner TB, Gordon SR et al. microRNA-10b expression correlates with response to neoadjuvant therapy and survival in pancreatic ductal adenocarcinoma. Clin. Cancer Res.17(17), 5812–5821 (2011).
   PubMed Web of Science ®Google Scholar
• Hotz B, Arndt M, Dullat S, Bhargava S, Buhr H-J, Hotz HG. Epithelial to mesenchymal transition: expression of the regulators Snail, Slug, and Twist in pancreatic cancer. Clin. Cancer Res.13(16), 4769–4776 (2007).
   PubMed Web of Science ®Google Scholar
• Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature449(7163), 682–688 (2007).
   PubMed Web of Science ®Google Scholar
• Gee HE, Camps C, Buffa FM et al. MicroRNA-10b and breast cancer metastasis. Nature455(7216), E8–E9 (2008).
   Web of Science ®Google Scholar
• Kent OA, Mullendore M, Wentzel EA et al. A resource for analysis of microRNA expression and function in pancreatic ductal adenocarcinoma cells. Cancer Biol. Ther.8(21), 2013–2024 (2009).
   PubMed Web of Science ®Google Scholar
• Turner BG, Cizginer S, Agarwal D, Yang J, Pitman MB, Brugge WR. Diagnosis of pancreatic neoplasia with EUS and FNA: a report of accuracy. Gastrointest. Endosc.71(1), 91–98 (2010).
   PubMed Web of Science ®Google Scholar
• Funel N, Giovannetti E, Pollina LE et al. Critical role of laser microdissection for genetic, epigenetic and proteomic analyses in pancreatic cancer. Expert Rev. Mol. Diagn.11(7), 695–701 (2011).
   PubMed Web of Science ®Google Scholar
• Schultz NA, Werner J, Willenbrock H et al. MicroRNA expression profiles associated with pancreatic cancer. J. Clin. Oncol.29(Suppl. 4), (2011) (Abstract 153).
   Google Scholar
• Roth C, Rack B, Muller V, Janni W, Pantel K, Schwarzenbach H. Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer. Breast Cancer Res.12(6), R90 (2010).
   PubMed Web of Science ®Google Scholar
• Obad S, Dos Santos CO, Petri A et al. Silencing of microRNA families by seed-targeting tiny LNAs. Nat. Genet.43(4), 371–378 (2011).
   PubMed Web of Science ®Google Scholar
• Lanford RE, Hildebrandt-Eriksen ES, Petri A et al. therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science327(5962), 198–201 (2010).
   PubMed Web of Science ®Google Scholar
• Pramanik D, Campbell NR, Karikari C et al. Restitution of tumor suppressor microRNAs using a systemic nanovector inhibits pancreatic cancer growth in mice. Mol. Cancer Ther.10(8), 1470–1480 (2011).
   PubMed Web of Science ®Google Scholar
• Ohuchida K, Mizumoto K, Kayashima T et al. MicroRNA expression as a predictive marker for gemcitabine response after surgical resection of pancreatic cancer. Ann. Surg. Oncol.18(8), 2381–2387 (2011).
   PubMed Web of Science ®Google Scholar
• Jamieson NB, Oien K, Imrie CW, Dickson EJ, Carter R, Mckay C. M1964 A microRNA prognostic signature for pancreatic ductal adenocarcinoma. Gastroenterology138(5), S449 (2010).
   Google Scholar
• Greither T, Grochola L, Udelnow A, Lautenschlager C, Wurl P, Taubert H. Elevated expression of microRNAs 155, 203, 210 and 222 in pancreatic tumours associates with poorer survival. Int. J. Cancer126(1), 73–80 (2010).
   PubMed Web of Science ®Google Scholar
• Kong X, Du Y, Wang G et al. Detection of differentially expressed microRNAs in serum of pancreatic ductal adenocarcinoma patients: miR-196a could be a potential marker for poor prognosis. Dig. Dis. Sci.56(2), 602–609 (2011).
   PubMedGoogle Scholar
• Ali S, Almhanna K, Chen W, Philip PA, Sarkar FH. Differentially expressed miRNAs in the plasma may provide a molecular signature for aggressive pancreatic cancer. Am. J. Transl. Res.3(1), 28–47 (2011).
   Web of Science ®Google Scholar
• Dillhoff M, Liu J, Frankel W, Croce C, Bloomston M. MicroRNA-21 is overexpressed in pancreatic cancer and a potential predictor of survival. J. Gastrointest. Surg.12(12), 2171–2176 (2008).
   PubMed Web of Science ®Google Scholar
• Yu J, Ohuchida K, Mizumoto K et al. MicroRNA, hsa-miR-200c, is an independent prognostic factor in pancreatic cancer and its upregulation inhibits pancreatic cancer invasion but increases cell proliferation. Mol. Cancer9, 169 (2010).
   PubMed Web of Science ®Google Scholar
• Hwang JH, Voortman J, Giovannetti E et al. Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer. PLoS One5(5), e10630 (2010).
   PubMed Web of Science ®Google Scholar
• Zhang XJ, Ye H, Zeng CW, He B, Zhang H, Chen YQ. Dysregulation of miR-15a and miR-214 in human pancreatic cancer. J. Hematol. Oncol.3, 46 (2010).
   PubMed Web of Science ®Google Scholar
• Giovannetti E, Funel N, Peters GJ et al. MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity. Cancer Res.70(11), 4528–4538 (2010).
   PubMed Web of Science ®Google Scholar
• Park JK, Lee EJ, Esau C, Schmittgen TD. Antisense inhibition of microRNA-21 or -221 arrests cell cycle, induces apoptosis, and sensitizes the effects of gemcitabine in pancreatic adenocarcinoma. Pancreas38(7), e190–e199 (2009).
   PubMed Web of Science ®Google Scholar
• Ali S, Ahmad A, Banerjee S et al. Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF. Cancer Res.70(9), 3606–3617 (2010).
   PubMed Web of Science ®Google Scholar
• Li Y, VandenBoom TG 2nd, Kong D et al. Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res.69(16), 6704–6712 (2009).
   PubMed Web of Science ®Google Scholar
• Ji Q, Hao X, Zhang M et al. MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. PLoS One4(8), e6816 (2009).
   PubMed Web of Science ®Google Scholar
• Dhayat S, Mardin WA, Mees ST, Haier J. Epigenetic markers for chemosensitivity and chemoresistance in pancreatic cancer – a review. Int. J. Cancer129(5), 1031–1041 (2011).
   PubMed Web of Science ®Google Scholar
• Wan Y, Chang HY. HOTAIR: Flight of noncoding RNAs in cancer metastasis. Cell Cycle9(17), 3391–3392 (2010).
   PubMed Web of Science ®Google Scholar
• Tian Y, Luo A, Cai Y et al. MicroRNA-10b promotes migration and invasion through KLF4 in human esophageal cancer cell lines. J. Biol. Chem.285(11), 7986–7994 (2010).
   PubMed Web of Science ®Google Scholar
• Reddy SDN, Ohshiro K, Rayala SK, Kumar R. MicroRNA-7, a Homeobox D10 target, inhibits p21-activated kinase 1 and regulates its functions. Cancer Res.68(20), 8195–8200 (2008).
   PubMed Web of Science ®Google Scholar
• Ma L. Role of miR-10b in breast cancer metastasis. Breast Cancer Res.12(5), 210 (2010).
   PubMed Web of Science ®Google Scholar